On October 23, 2023, Cell Impact AB (publ) (the "Company") disclosed a press release with information that the Company intends to resolve on a rights issue. The press release also stated that the Company had entered into bridge loan agreements which would ensure sufficient liquidity during the period November until December 2023. The payment of the bridge loan to the Company is among other things conditional upon the board of directors resolving on the rights issue after obtaining authorization from an extraordinary general meeting in the Company. The rules of Nasdaq First North Growth Market state that an issuer can be given observation status if there is material adverse uncertainty in respect of the issuer's financial position. With reference to the above, Nasdaq Stockholm AB decides that the shares in Cell Impact AB (publ) (CI, ISIN code SE0017885379, order book ID 92429) shall be given observation status. For further information about this exchange notice please contact Enforcement & Investigations, telephone +46 8 405 70 50.
© 2023 GlobeNewswire
